Sodium Hydroxide → 2-Hydroxyabacavir
反応式
[NH2:1][C:2]1[N:10]=[C:9]2[C:5]([N:6]=[CH:7][N:8]2[C@H:11]2[CH2:15][C@H:14]([OH:16])[C@@H:13]([CH2:17][OH:18])[CH2:12]2)=[C:4](Cl)[N:3]=1.[CH:20]1([NH2:23])[CH2:22][CH2:21]1.[OH-].[Na+]>C(O)C>[NH2:1][C:2]1[N:10]=[C:9]2[C:5]([N:6]=[CH:7][N:8]2[C@H:11]2[CH2:15][C@H:14]([OH:16])[C@@H:13]([CH2:17][OH:18])[CH2:12]2)=[C:4]([NH:23][CH:20]2[CH2:22][CH2:21]2)[N:3]=1参加物
実験手順
(+)-(1S, 2R, 4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl) cyclopentanol (425 mg, 1.5 mmol), cyclopropylamine (Aldrich, 1.4 mL), and ethanol (4 mL) were refluxed for 3 hours. To the cooled solution was added 1N sodium hydroxide (1.5 mL). The residual oil left on evaporation of volatiles under vacuum was chromatographed on silica gel. Title compound was eluted with methanol ethyl acetate/15:85 as a white solid foam which solidified to white powder in methanol-acetonitrile (309 mg, 68%); m.p. 174°-176° C.; mass spectrum (Cl,CH4)305 (M+1); 1H-NMR(DMSO-d6) δ: 7.79 (s, 1, H-8); 7.25 (d, J=2.9 Hz, 1, NH), 5.79 (s, 2, NH2), 4.90-4.75 (m, 1, CH-N), 4.73 (d, J=4.0 Hz, 1, OH), 4.63 (t, J=5.3 Hz, 1, CHOH), 4.08-4.00 (m, 1, CHO), 3.58-3.38 (m, 2, CH2O), 3.05-2.95 (m, 1 CH-NH), 2.35-2.20(m, 1, CH), 2.18-2.0 (m, 1, 1/2CH2), 2.0-1.9 (m, 2, methylene), 1.7-1.5 (m, 1, 1/2CH2),0.70-0.50 m, 4, 2CH2 of cyclopropyl); [α]20589 +7.72°, [α]20 578 +7.87°, [α]20546 +8.77°, [α]20436 +14.4°, [α]20365 +20.1°(c=0.65, methanol).
後処理
- waitThe residual oil left on evaporation of volatiles under vacuum
- customwas chromatographed on silica gel
- washTitle compound was eluted with methanol ethyl acetate/15:85 as a white solid foam which
- custom[α]20589 +7.72°, [α]20 578 +7.87°, [α]20546 +8.77°, [α]20436 +14.4°, [α]20365 +20.1°(c=0.65, methanol)
出典と根拠
- ORDレコード
- ord-ae2a06412b0d4b55b08730d083771a73
- 出典データセット
- uspto-grants-1997_06
- 特許番号
- US05641889
反応ノート
読み込み中…